

Evidence of scar tissue: contra-indication to cardiac resynchronization therapy?

E. E. van der Wall · M. J. Schalij · H. F. Verwey · J. J. Bax

Received: 21 June 2010 / Accepted: 25 June 2010 / Published online: 8 July 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com

Cardiac resynchronization therapy (CRT) has shown to be an effective treatment for patients with advanced heart failure (HF) (NYHA Class III or IV), reduced left ventricular ejection fraction (LVEF < 35%) and wide QRS complexes (>120 ms) [1, 2]. The beneficial effects include improvement in heart failure symptoms, exercise capacity, and left ventricular function, as well as less heart failure hospitalizations and lower mortality rates. Despite these remarkable results, 30–40% of patients show no benefit after CRT, the so-called ‘non-responders’ [3–5]. It remains, however, difficult to distinguish responders from non-responders in the early period after CRT. The presence of LV dyssynchrony prior to implantation and its subsequent reduction after implantation have been proposed as the key mechanisms for a positive response to CRT [6].

A variety of imaging modalities has already been applied to identify dyssynchrony and to evaluate the effects of CRT [7–10]. The use of echocardiography [11–17], magnetic resonance imaging (MRI) [18–29],

and multi-slice computed tomography (MSCT) [30–43] has recently been proven for patients eligible for CRT. In addition, nuclear imaging techniques have become suited for the evaluation of LV dyssynchrony [44–51]. Until now, scintigraphic studies in CRT mainly concerned radionuclide angiography with phase image analysis [52–56]. In recent years positron emission tomography (PET) has emerged as a suitable modality to study the metabolic mechanisms of left ventricular dyssynchrony and the effects of CRT. Several studies did already report that ¹¹C-acetate PET performed in the chronic phase after CRT showed improvement of oxygen metabolism and cardiac efficiency by CRT [57, 58].

In the current issue in the *International Journal of Cardiovascular Imaging*, Zacá et al. [59] provide an interesting analysis about the selection of candidates to CRT beyond responders and non-responders with the perspective of the potential identification of patients who will not respond to CRT. The authors clearly state that of all evaluated indices of mechanical dyssynchrony only a QRS duration of >120 ms is recommended in current treatment guidelines for the selection of candidates to CRT. No conclusive evidence is currently available about which of the many variables can predict individual response and should be included in selection criteria. The disappointing results of the PROSPECT trial may be due to high variability in tissue Doppler imaging (TDI) measurements and pathophysiological issues potentially affecting response to CRT mainly in ischemic

Editorial comment to the article by Zacá et al.
doi:10.1007/s10554-010-9651-y.

E. E. van der Wall (✉) · M. J. Schalij ·
H. F. Verwey · J. J. Bax
Department of Cardiology, Leiden University Medical
Center, P.O. Box 9600, Leiden, The Netherlands
e-mail: e.e.van_der_wall@lumc.nl

patients [60]. Zacá et al. [59] challenge the view that patients with ischemic cardiomyopathy and extensive scar tissue should be withheld CRT. Several studies by the group of Bax [29, 61, 62] have shown that the presence of postero-lateral scar tissue diagnosed by contrast-enhanced MRI resulted in ineffective CRT in 30–40% of patients with ischemic heart failure. Using biventricular pacing, left ventricular dyssynchrony remained unchanged, and there were no functional improvements at 6 months follow-up. The results of these studies have been confirmed by many other studies that showed a clear negative association between scar burden and the response to CRT [63–68]. Notwithstanding, it is the belief of Zacá et al. [59] that these observations and the ensuing implications not to treat with CRT are too preliminary. The value of CRT in this subset of ischemic heart failure patients would mandate larger multi-center studies. In their vision, even non-responders should receive a CRT device whereby the certain risk of withholding the treatment might be more consistent than the potential risk of being a non-responder. This point of view is in line with the recent study by Riedlbauchová et al. [69], who showed that the response to CRT was independent of the presence of extensive myocardial scarring. It was shown that left ventricular pacing at sites with ischemia, hibernation, or non-transmural scar did not appear to modify the effect of CRT as compared to viable tissue. It follows that incorporation in the standard selection criteria of algorithms to predict the response to CRT is yet not ready for clinical use. To this purpose, appropriate application of sophisticated imaging techniques may improve efficacy of resynchronization in the subset of ischemic patients who might respond to CRT. Therefore, identification of these individuals by means of echocardiography, nuclear cardiology, MSCT or MRI potentially has substantial implications in defining the optimal strategy for device implantation. In this respect, consistent data are likely to be expected from echocardiographic studies using advanced measures of mechanical dyssynchrony such as two-dimensional strain imaging, speckle tracking, and real-time three-dimensional echocardiography [15, 17, 70–76]. Although it appears legitimate to withhold CRT in patients with ischemic cardiomyopathy who show extensive scar tissue, a definite treatment policy in these patients can only be fully embraced after supportive data from large multi-center studies.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Bax JJ, Marwick TH, Molhoek SG et al (2003) Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. *Am J Cardiol* 92: 1238–1240
2. Bax JJ, Bleeker GB, Marwick TH et al (2004) Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. *J Am Coll Cardiol* 44:1834–1840
3. Buck S, Maass AH, van Veldhuisen DJ, Van Gelder IC (2009) Cardiac resynchronisation therapy and the role of optimal device utilisation. *Neth Heart J* 17:354–357
4. van Hemel NM, Scheffer M (2009) Cardiac resynchronization therapy in daily practice and loss of confidence in predictive techniques to response. *Neth Heart J* 17:4–5
5. Bleeker GB, Holman ER, Steendijk P et al (2006) Cardiac resynchronization therapy in patients with a narrow QRS complex. *J Am Coll Cardiol* 48:2243–2250
6. Jansen AH, van Gelder BM (2008) Visual LV motion and invasive LVdP/dtmax for selection and optimisation of cardiac resynchronisation therapy. *Neth Heart J* 16(Suppl 1):S32–S35
7. Sá MI, de Roos A, Westenberg JJ, Kroft LJ (2008) Imaging techniques in cardiac resynchronization therapy. *Int J Cardiovasc Imaging* 24:89–105
8. Ypenburg C, van der Wall EE, Schalij MJ, Bax JJ (2008) Imaging in cardiac resynchronisation therapy. *Neth Heart J* 16:S36–S40
9. Ypenburg C, Westenberg JJ, Bleeker GB et al (2008) Noninvasive imaging in cardiac resynchronization therapy—part 1: selection of patients. *Pacing Clin Electrophysiol* 31:1475–1499
10. Van de Veire NR, Delgado V, Schuijff JD, van der Wall EE, Schalij MJ, Bax JJ (2009) The role of non-invasive imaging in patient selection. *Europace* 11(Suppl 5): v32–v39
11. Bleeker GB, Bax JJ, Fung JW et al (2006) Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. *Am J Cardiol* 97:260–263
12. Bleeker GB, Yu CM, Nihoyannopoulos P et al (2007) Optimal use of echocardiography in cardiac resynchronization therapy. *Heart* 93:1339–1350
13. Bleeker GB, Schalij MJ, Boersma E et al (2007) Relative merits of M-mode echocardiography and tissue Doppler imaging for prediction of response to cardiac resynchronization therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 99:68–74
14. Bertini M, Marsan NA, Delgado V et al (2009) Effects of cardiac resynchronization therapy on left ventricular twist. *J Am Coll Cardiol* 54:1317–1325

15. Tops LF, Suffoletto MS, Bleeker GB et al (2007) Speckle tracking radial strain reveals left ventricular dyssynchrony in patients with permanent right ventricular pacing. *J Am Coll Cardiol* 50:1180–1188
16. Shi H, Shu X, Wang F et al (2009) Longitudinal two-dimensional strain rate imaging: a potential approach to predict the response to cardiac resynchronization therapy. *Int J Cardiovasc Imaging* 25:677–687
17. Pavlopoulos H, Nihoyannopoulos P (2010) Recent advances in cardiac resynchronization therapy: echocardiographic modalities, patient selection, optimization, non-responders all you need to know for more efficient CRT. *Int J Cardiovasc Imaging* 26:177–191
18. van der Wall EE, van Dijkman PR, de Roos A et al (1990) Diagnostic significance of gadolinium-DTPA (diethylenetriamine penta-acetic acid) enhanced magnetic resonance imaging in thrombolytic treatment for acute myocardial infarction: its potential in assessing reperfusion. *Br Heart J* 63:12–17
19. van Dijkman PR, van der Wall EE, de Roos A et al (1991) Acute, subacute, and chronic myocardial infarction: quantitative analysis of gadolinium-enhanced MR images. *Radiology* 180:147–151
20. de Roos A, Matheijssen NA, Doornbos J, van Dijkman PR, van Voorthuisen AE, van der Wall EE (1990) Myocardial infarct size after reperfusion therapy: assessment with Gd-DTPA-enhanced MR imaging. *Radiology* 176:517–521
21. Pluim BM, Lamb HJ, Kayser HW et al (1998) Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. *Circulation* 97:666–672
22. Vliegen HW, Doornbos J, de Roos A, Jukema JW, Bekedam MA, van der Wall EE (1997) Value of fast gradient echo magnetic resonance angiography as an adjunct to coronary arteriography in detecting and confirming the course of clinically significant coronary artery anomalies. *Am J Cardiol* 79:773–776
23. Hoogendoorn LI, Pattynama PM, Buis B, van der Geest RJ, van der Wall EE, de Roos A (1995) Noninvasive evaluation of aortocoronary bypass grafts with magnetic resonance flow mapping. *Am J Cardiol* 75:845–848
24. van der Geest RJ, Niezen RA, van der Wall EE, de Roos A, Reiber JH (1998) Automated measurement of volume flow in the ascending aorta using MR velocity maps: evaluation of inter- and intraobserver variability in healthy volunteers. *J Comput Assist Tomogr* 22:904–911
25. Rolink AM, Verheugt FW, Bosker HA (2009) Cardiac resynchronization therapy: results from daily practice in Rijnstate Hospital, Arnhem. *Neth Heart J* 17:6–8
26. Ypenburg C, Roes SD, Bleeker GB et al (2007) Effect of total scar burden on contrast-enhanced magnetic resonance imaging on response to cardiac resynchronization therapy. *Am J Cardiol* 99:657–660
27. Rüssel IK, van Dijk J, Kleijn SA et al (2009) Relation between three-dimensional echocardiography derived left ventricular volume and MRI derived circumferential strain in patients eligible for cardiac resynchronization therapy. *Int J Cardiovasc Imaging* 25:1–11
28. Westenberg JJ, Lamb HJ, van der Geest RJ et al (2006) Assessment of left ventricular dyssynchrony in patients with conduction delay and idiopathic dilated cardiomyopathy: head-to-head comparison between tissue Doppler imaging and velocity-encoded magnetic resonance imaging. *J Am Coll Cardiol* 47:2042–2048
29. Bleeker GB, Kaandorp TA, Lamb HJ et al (2006) Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. *Circulation* 113:969–976
30. Schuijf JD, Pundziute G, Jukema JW et al (2006) Diagnostic accuracy of 64-slice multislice computed tomography in the noninvasive evaluation of significant coronary artery disease. *Am J Cardiol* 98:145–148
31. Groen JM, Greuter MJ, Vliegenthart R et al (2008) Calcium scoring using 64-slice MDCT, dual source CT and EBT: a comparative phantom study. *Int J Cardiovasc Imaging* 24:547–556
32. de Leeuw JG, Wardeh A, Sramek A, van der Wall EE (2007) Pseudo-aortic dissection after primary PCI. *Neth Heart J* 15:265–266
33. Steendijk P, Tulner SA, Bax JJ et al (2006) Hemodynamic effects of long-term cardiac resynchronization therapy: analysis by pressure-volume loops. *Circulation* 113:1295–1304
34. Portegies MC, Schmitt R, Kraaij CJ et al (1991) Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. *J Cardiovasc Pharmacol* 18:746–751
35. ten Kate GJ, Wuestink AC, de Feyter PJ (2008) Coronary artery anomalies detected by MSCT-angiography in the adult. *Neth Heart J* 16:369–375
36. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I (1995) Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group. *Am Heart J* 130:748–757
37. Schuijf JD, Jukema JW, van der Wall EE, Bax JJ (2007) Multi-slice computed tomography in the evaluation of patients with acute chest pain. *Acute Card Care* 9: 214–221
38. Henneman MM, Schuijf JD, Pundziute G et al (2008) Noninvasive evaluation with multislice computed tomography in suspected acute coronary syndrome: plaque morphology on multislice computed tomography versus coronary calcium score. *J Am Coll Cardiol* 52:216–222
39. de Nooijer R, Verkleij CJ, von der Thüsen JH et al (2006) Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. *Arterioscler Thromb Vasc Biol* 26:340–346
40. van der Laarse A, Kerkhof PL, Vermeer F et al (1988) Relation between infarct size and left ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment. *Am J Cardiol* 61:1–7
41. Oemrawsingh PV, Mintz GS, Schaliq MJ, Zwinderman AH, Jukema JW, van der Wall EE (2003) Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison

- with angiographic guidance (TULIP Study). *Circulation* 107:62–67
42. Jongbloed MR, Lamb HJ, Bax JJ et al (2005) Noninvasive visualization of the cardiac venous system using multislice computed tomography. *J Am Coll Cardiol* 45:749–753
 43. Van de Veire NR, Schuijff JD, De Sutter J et al (2006) Non-invasive visualization of the cardiac venous system in coronary artery disease patients using 64-slice computed tomography. *J Am Coll Cardiol* 48:1832–1838
 44. van der Wall EE, Heidendal GA, den Hollander W, Westera G, Roos JP (1980) I-123 labeled hexadecenoic acid in comparison with thallium-201 for myocardial imaging in coronary heart disease. A preliminary study. *Eur J Nucl Med* 5:401–405
 45. Bax JJ, Lamb H, Dibbets P et al (2000) Comparison of gated single-photon emission computed tomography with magnetic resonance imaging for evaluation of left ventricular function in ischemic cardiomyopathy. *Am J Cardiol* 86:1299–1305
 46. Bavelaar-Croon CD, Pauwels EK, van der Wall EE (2001) Gated single-photon emission computed tomographic myocardial imaging: a new tool in clinical cardiology. *Am Heart J* 141:383–390
 47. Chamuleau SA, van Eck-Smit BL, Meuwissen M et al (2007) Long-term prognostic value of CFVR and FFR versus perfusion scintigraphy in patients with multivessel disease. *Neth Heart J* 15:369–374
 48. Groenink M, Lohuis TA, Tijssen JG et al (1999) Survival and complication free survival in Marfan's syndrome: implications of current guidelines. *Heart* 82:499–504
 49. van Ruge FP, Boreel JJ, van der Wall EE et al (1991) Cardiac first-pass and myocardial perfusion in normal subjects assessed by sub-second Gd-DTPA enhanced MR imaging. *J Comput Assist Tomogr* 15:959–965
 50. van der Wall EE, den Hollander W, Heidendal GA, Westera G, Majid PA, Roos JP (1981) Dynamic myocardial scintigraphy with 123I-labeled free fatty acids in patients with myocardial infarction. *Eur J Nucl Med* 6:383–389
 51. Ypenburg C, Schalij MJ, Bleeker GB et al (2006) Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. *J Nucl Med* 47:1565–1570
 52. Henneman MM, van der Wall EE, Ypenburg C et al (2007) Nuclear imaging in cardiac resynchronization therapy. *J Nucl Med* 48:2001–2010
 53. Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE (2002) Risk factors for coronary heart disease: implications of gender. *Cardiovasc Res* 53:538–549
 54. Boogers MM, Chen J, Bax JJ (2008) Myocardial perfusion single photon emission computed tomography for the assessment of mechanical dyssynchrony. *Curr Opin Cardiol* 23:431–439
 55. Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR (2005) Risks of oral anticoagulant therapy with increasing age. *Arch Intern Med* 165:1527–1532
 56. Henneman MM, Chen J, Dibbets-Schneider P et al (2007) Dyssynchrony as assessed with phase analysis on gated myocardial perfusion SPECT predict response to CRT? *J Nucl Med* 48:1104–1111
 57. Kitaizumi K, Yukiiri K, Masugata H et al (2010) Acute improvement of cardiac efficiency measured by 11C-acetate PET after cardiac resynchronization therapy and clinical outcome. *Int J Cardiovasc Imaging* 26:285–292
 58. Umar S, Bax JJ, Klok M et al (2008) Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy. *Eur J Heart Fail* 10:878–883
 59. Zacà V, Mondillo S, Gaddi R, Favilli R (2010) Profiling cardiac resynchronization therapy patients: responders, non-responders and those who cannot respond—*The good, the bad and the ugly?* *Int J Cardiovasc Imaging*. doi: 10.1007/s10554-010-9651-y
 60. Chung ES, Leon AR, Tavazzi L et al (2008) Results of the 489 predictors of response to CRT (PROSPECT) trial. *Circulation* 117:2608–2616
 61. Ypenburg C, Schalij MJ, Bleeker GB et al (2007) Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. *Eur Heart J* 28:33–41
 62. Marsan NA, Westenberg JJ, Ypenburg C et al (2009) Magnetic resonance imaging and response to cardiac resynchronization therapy: relative merits of left ventricular dyssynchrony and scar tissue. *Eur Heart J* 30:2360–2367
 63. White JA, Yee R, Yuan X et al (2006) Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. *J Am Coll Cardiol* 48:1953–1960
 64. Chalil S, Stegemann B, Muhyaldeen SA et al (2007) Effect of posterolateral left ventricular scar on mortality and morbidity following cardiac resynchronization therapy. *Pacing Clin Electrophysiol* 30:1201–1209
 65. Adelstein EC, Saba S (2007) Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. *Am Heart J* 153:105–112
 66. Bilchick KC, Dimaano V, Wu KC et al (2008) Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. *JACC Cardiovasc Imaging* 1:561–568
 67. D'Andrea A, Caso P, Scarafilo R et al (2009) Effects of global longitudinal strain and total scar burden on response to cardiac resynchronization therapy in patients with ischaemic dilated cardiomyopathy. *Eur J Heart Fail* 11:58–67
 68. Birnie D, DeKemp RA, Ruddy TD et al (2009) Effect of lateral wall scar on reverse remodeling with cardiac resynchronization therapy. *Heart Rhythm* 6:1721–1726
 69. Riedlbauchová L, Brunken R, Jaber WA et al (2009) The impact of myocardial viability on the clinical outcome of cardiac resynchronization therapy. *J Cardiovasc Electro-physiol* 20:50–57
 70. Molhoek SG, Bax JJ, van Erven L et al (2004) Comparison of benefits from cardiac resynchronization therapy in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy. *Am J Cardiol* 93:860–863
 71. Molhoek SG, Van Erven L, Bootsma M, Steendijk P, Van Der Wall EE, Schalij MJ (2004) QRS duration and shortening to predict clinical response to cardiac

- resynchronization therapy in patients with end-stage heart failure. *Pacing Clin Electrophysiol* 27:308–313
72. Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ (2006) Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. *J Am Coll Cardiol* 48:1642–1648
 73. Tops LF, Bax JJ, Zeppenfeld K et al (2005) Fusion of multislice computed tomography imaging with three-dimensional electroanatomic mapping to guide radiofrequency catheter ablation procedures. *Heart Rhythm* 2: 1076–1081
 74. Ypenburg C, Van De Veire N, Westenberg JJ et al (2008) Noninvasive imaging in cardiac resynchronization therapy-Part 2: follow-up and optimization of settings. *Pacing Clin Electrophysiol* 31:1628–1639
 75. Marsan NA, Bleeker GB, Van Bommel RJ et al (2009) Cardiac resynchronization therapy in patients with ischemic versus non-ischemic heart failure: differential effect of optimizing interventricular pacing interval. *Am Heart J* 158:769–776
 76. Delgado V, Mooyaart EA, Ct Ng A et al (2010) Echocardiography and non-invasive imaging in cardiac resynchronization therapy. *Minerva Cardioangiol* 58:313–332